期刊文献+
共找到500篇文章
< 1 2 25 >
每页显示 20 50 100
Real World Evidence (RWE, Real World Data), of the Effectiveness of Amoxicillin-Clavulanate in the Treatment of Children with Upper Respiratory Tract Infections (Tonsillitis, Otitis, Sinusitis)
1
作者 Maria Gonzalez Yibirin Juan Chirinos +28 位作者 David Alberto Rincón Matute Trinidad Coll Miriam Rosales Yuliana Guevara Kuanlin Doried Guitens Pérez Mauribel Figueroa Rosalía Romero Jurgensen Andrea Rojas Gabriel Jesús Arismendi González Milagros Salcedo Marife Martina Marin Marcano Carolina Mendoza Marycarmen Anuel Maria Morao Raymond Aguilera Diego Ríos Maryenis Rodríguez Loren Sánchez Jennyfer Fernández Rafael González Zaidith Zerpa Nelson Rodríguez Mirluis Rojas Sixtaime Quijada Mariangel Moya Diego Orsini Chris Gómez Hector Gamero José Rodríguez 《Open Journal of Respiratory Diseases》 2024年第3期77-89,共13页
Real-world evidence (RWE) is clinical evidence on a medical product’s safety and efficacy that is generated using real-world data (RWD) resulting from routine healthcare delivery. This study evaluates the clinical ef... Real-world evidence (RWE) is clinical evidence on a medical product’s safety and efficacy that is generated using real-world data (RWD) resulting from routine healthcare delivery. This study evaluates the clinical efficacy of amoxicillin + clavulanic acid in children with pharyngitis, acute otitis, or acute rhinosinusitis with suspected bacterial origin under normal office and home conditions. Methods: This was a real-life, prospective, observational, pharmacovigilance study. It included children of both sexes between 2 and 12 years old, with a diagnosis of Rhinopharyngitis (tonsillitis), Acute Otitis Media and Rhinosinusitis. The main effectiveness variable evaluated was reduction and time to resolution of symptoms. All patients received Amoxicillin/Clavulanic Acid suspension 600 mg/42.9 mg/5 mL at a dose of 90 mg/Kg/day in two doses, every 12 hours for 7 days. The evaluations were carried out at the beginning, at 72 hours (3rd day) and at 7 days. All patients underwent culture and antibiogram. Results: The majority of cultures were negative for pathogenic germs, suspecting unidentifiable germs, or viral etiology despite the rigorous selection of subjects following validated scores. The most frequently isolated germ was Staphylococcus aureus;growth of gram-negative bacteria was reported in 33.33% of the cultures. There was a significant improvement in symptoms in children with tonsillitis and rhinosinusitis from the first 72 hours of treatment, persisting until the 7 days. In the otitis media group, returning to normal by the tenth day. During the conduction of this investigation, no adverse effects associated with the prescribed therapy were reported. 展开更多
关键词 amoxicillin clavulanic Acid TONSILLITIS OTITIS SINUSITIS
下载PDF
Bioequiwalence of clavulanate Potassium and Amoxicillin(1:7) dispersible tablets in healthy volunteers
2
作者 胡国新 代宗顺 +3 位作者 龙利红 韩颖 侯淑贤 吴立 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2002年第3期224-227,共4页
To study the bioequivalence of Clavulanate Potassium and Amoxicillin (1:7) dispersible tablets, a randomized cross over study was conducted in 18 healthy volunteers. A single oral dose of 1000 mg Clav ulanate Pot... To study the bioequivalence of Clavulanate Potassium and Amoxicillin (1:7) dispersible tablets, a randomized cross over study was conducted in 18 healthy volunteers. A single oral dose of 1000 mg Clav ulanate Potassium and Amoxicillin (1:7) dispersible tablets (Tested formulation, T) or Augmentin syrup (Reference formulation, R). Concentrations in plasma were determined with high performance liquid chromatography. The main paramaters of T were: for Clavulanate Potassium and Amoxicillin, C max : 2.46±1.11 μg/m l and 18.81±7.26 μg/ml, T max : 1.12±0.23h and 1.30±0.34h, AUC (0 - 6 h) : 5.18±2.24 μg·h/ml and 45.09±14.53 μg·h/ml, t 1/2 : 1.43±0.44 h and 1.09±0.22 h., respectively. The relative bioavailability of T to R were 9 6.5±19.2 % and 98.4±26.1 % , respectively. Statistical analysis showed that th e two formulations were bioequivalent. 展开更多
关键词 clavulanate potassium amoxicillin pharmacoki netics BIOAVAILABILITY
下载PDF
Acute cholestatic hepatitis caused by amoxicillin/ clavulanate 被引量:3
3
作者 Daniel Oliveira Beraldo Joanderson Fernandes Melo +3 位作者 Alexandre Vidal Bonfim Andrei Alkmim Teixeira Ricardo Alkmim Teixeira André Loyola Duarte 《World Journal of Gastroenterology》 SCIE CAS 2013年第46期8789-8792,共4页
Amoxicillin/clavulanate is a synthetic penicillin that is currently commonly used,especially for the treatment of respiratory and cutaneous infections.In general,it is a well-tolerated oral antibiotic.However,amoxicil... Amoxicillin/clavulanate is a synthetic penicillin that is currently commonly used,especially for the treatment of respiratory and cutaneous infections.In general,it is a well-tolerated oral antibiotic.However,amoxicillin/clavulanate can cause adverse effects,mainly cutaneous,gastrointestinal,hepatic and hematologic,in some cases.Presented here is a case report of a 63-yearold male patient who developed cholestatic hepatitis after recent use of amoxicillin/clavulanate.After 6 wk of prolonged use of the drug,he began to show signs of cholestatic icterus and developed severe hyperbilirubinemia(total bilirubin>300 mg/L).Diagnostic investigation was conducted by ultrasonography of the upper abdomen,serum tests for infection history,laboratory screening of autoimmune diseases,nuclear magnetic resonance(NMR)of the abdomen with bile duct-NMR and transcutaneous liver biopsy guided by ultrasound.The duration of disease was approximately 4 mo,with complete resolution of symptoms and laboratory changes at the end of that time period.Specific treatment was not instituted,only a combination of anti-emetic(metoclopramide)and cholestyramine for pruritus. 展开更多
关键词 HEPATOLOGY HEPATITIS amoxicillin/Clavula-nate Drug REACTIONS HYPERBILIRUBINEMIA
下载PDF
Treatment of Helicobacter pylori with potassium competitive acid blockers:A systematic review and meta-analysis
4
作者 Joseph Edwin Kanu Jonathan Soldera 《World Journal of Gastroenterology》 SCIE CAS 2024年第9期1213-1223,共11页
BACKGROUND Helicobacter pylori(H.pylori)infects over half the global population,causing gastrointestinal diseases like dyspepsia,gastritis,duodenitis,peptic ulcers,GMALT lymphoma,and gastric adenocarcinoma.Eradicating... BACKGROUND Helicobacter pylori(H.pylori)infects over half the global population,causing gastrointestinal diseases like dyspepsia,gastritis,duodenitis,peptic ulcers,GMALT lymphoma,and gastric adenocarcinoma.Eradicating H.pylori is crucial for treating and preventing these conditions.While conventional proton pump inhibitor(PPI)-based triple therapy is effective,there’s growing interest in longer acid suppression therapies.Potassium competitive acid blocker(P-CAB)triple and dual therapy are new regimens for H.pylori eradication.Initially used in Asian populations,vonoprazan(VPZ)has been recently Food and Drug Administration-approved for H.pylori eradication.AIM To assess the efficacy of regimens containing P-CABs in eradicating H.pylori infection.METHODS This study,following PRISMA 2020 guidelines,conducted a systematic review and meta-analysis by searching MEDLINE and Scopus libraries for randomized clinical trials(RCTs)or observational studies with the following command:[("Helicobacter pylori"OR"H pylori")AND("Treatment"OR"Therapy"OR"Eradication")AND("Vonaprazan"OR"Potassium-Competitive Acid Blocker"OR"P-CAB"OR"PCAB"OR"Revaprazan"OR"Linaprazan"OR"Soraprazan"OR"Tegoprazan")].Studies comparing the efficacy of P-CABs-based treatment to classical PPIs in eradicating H.pylori were included.Exclusion criteria included case reports,case series,unpublished trials,or conference abstracts.Data variables encompassed age,diagnosis method,sample sizes,study duration,intervention and control,and H.pylori eradication method were gathered by two independent reviewers.Meta-analysis was performed in R software,and forest plots were generated.RESULTS A total of 256 references were initially retrieved through the search command.Ultimately,fifteen studies(7 RCTs,7 retrospective observational studies,and 1 comparative unique study)were included,comparing P-CAB triple therapy to PPI triple therapy.The intention-to-treat analysis involved 8049 patients,with 4471 in the P-CAB intervention group and 3578 in the PPI control group across these studies.The analysis revealed a significant difference in H.pylori eradication between VPZ triple therapy and PPI triple therapy in both RCTs and observational studies[risk ratio(RR)=1.17,95%confidence interval(CI):1.11-1.22,P<0.0001]and(RR=1.13,95%CI:1.09-1.17,P<0.0001],respectively.However,no significant difference was found between tegoprazan(TPZ)triple therapy and PPI triple therapy in both RCTs and observational studies(RR=1.04,95%CI:0.93-1.16,P=0.5)and(RR=1.03,95%CI:0.97-1.10,P=0.3),respectively.CONCLUSION VPZ-based triple therapy outperformed conventional PPI-based triple therapy in eradicating H.pylori,positioning it as a highly effective first-line regimen.Additionally,TPZ-based triple therapy was non-inferior to classical PPI triple therapy. 展开更多
关键词 Helicobacter pylori infection potassium competitive acid blockers Proton pump inhibitors Vonoprazan amoxicillin
下载PDF
Cefprozil versus Amoxicillin/Clavulanate for the Treatment of Acute Otitis Media in Children: Meta-Analysis of Efficacy and Safety 被引量:1
5
作者 Rafael Bolanos-Diaz Maria Calderon-Cahua 《Pharmacology & Pharmacy》 2014年第4期386-394,共9页
Introduction: The efficacy of amoxicillin combined with clavulanic acid in Acute Otitis Media (AOM) is not debatable, but studies report a high frequency of gastrointestinal adverse effects related to this interventio... Introduction: The efficacy of amoxicillin combined with clavulanic acid in Acute Otitis Media (AOM) is not debatable, but studies report a high frequency of gastrointestinal adverse effects related to this intervention. In this scenario, several studies about the antibiotic cefprozil report that it has the same efficacy as amoxicillin/clavulanate for the treatment of AOM with significantly fewer side effects. The aim of our study was to compare the efficacy and safety of both treatments in AOM. Methodology: We searched for clinical trials and systematic reviews with or without meta-analyses in the Cochrane Group Register and the MEDLINE database up to November 2013, comparing the two interventions mentioned. Results were expressed as a rate of treatment failures or favorable response rates (clinical and microbiological in both cases), and as the rate of adverse events. The analysis was carried out considering the fixed and random effects models. The significance level used in the test for heterogeneity was 0.05. Funnel plot was used to search for publication bias. Results: 7 clinical trials were included in the analysis and no significant difference was found for both interventions regarding clinical and bacteriological response (RR = 1.02, 95% CI, 0.97-1.06, p = 0.780 and RR = 1.02, 95% CI, 0.99-1.07, p = 0.228, respectively). However, a significant difference was found in the comparison of adverse effects, showing that amoxicillin/clavulanate has a significantly higher risk of developing side effects than cefprozil (RR = 0.52, 95% CI, 0.45-0.59, p = 0.000). Conclusion: Both treatments demonstrated equal clinical and microbiological efficacy. However, the use of cefprozil is significantly associated with a lower risk of adverse effects. 展开更多
关键词 CEFPROZIL amoxicillin/clavulanate Acute Otitis Media
下载PDF
Development and Validation of Stability Indicating HPLC Method for Simultaneous Estimation of Amoxicillin and Clavulanic Acid in Injection 被引量:2
6
作者 Durga Mallikarjuna Rao Tippa N. Singh 《American Journal of Analytical Chemistry》 2010年第3期95-101,共7页
A simple, fast, precise, accurate and rugged stability indicating high performance liquid chromatography (HPLC) method has been developed for simultaneous estimation of Amoxicillin and Clavulanic acid from injectable ... A simple, fast, precise, accurate and rugged stability indicating high performance liquid chromatography (HPLC) method has been developed for simultaneous estimation of Amoxicillin and Clavulanic acid from injectable dosage form. The stability indicating capability of the method was proven by subjecting the drugs to stress conditions as per ICH recommended test conditions such as alkaline and acid hydrolysis, oxidation, photolysis, thermal degradation and resolution of the degradation products formed therein. The separation was obtained using a mobile phase composition at a ratio of 95:5 (v/v) of pH 5.0 buffer and methanol on Inertsil C18 column (250 × 4.0 mm, 4 μm) with UV detection at 220 nm at a flow rate of 1 ml/minute. The photodiode array detector was used for stress studies. The order of elution of peaks was Clavulanic acid followed by Amoxicillin. The linear calibration range was found to be 79.51 to 315.32 μg/ml for Amoxicillin and 17.82 to 67.90 μg/ml for Clavulanic acid. The Amoxicillin and Clavulanic acid were found to be stable in solution up to 24 hours. The method validation data showed excellent results for precision, linearity, specificity, limit of detection, limit of quantification and robustness. The present method can be successfully used for routine quality control and stability studies. 展开更多
关键词 amoxicillin clavulanic ACID HPLC STABILITY Indicating
下载PDF
Amoxicillin–clavulanic acid induced sperm abnormalities and histopathological changes in mice
7
作者 Maha A. Fahmy Ayman A. Farghaly +5 位作者 Enayat A. Omara Zeinab M. Hassan Fawzia A.E. Aly Souria M. Donya Aziza A.E. Ibrahim Elsayed M. Bayoumy 《Asian Pacific Journal of Tropical Biomedicine》 SCIE CAS 2017年第9期809-816,共8页
Objective: To explore the genotoxic potential and histopathological changes induced in liver, kidney, testis, brain and heart after using the antibiotic drug amoxicillin/clavulanic acid(4:1).Methods: The study include... Objective: To explore the genotoxic potential and histopathological changes induced in liver, kidney, testis, brain and heart after using the antibiotic drug amoxicillin/clavulanic acid(4:1).Methods: The study included chromosomal aberration analysis in bone-marrow and mouse spermatocytes, induction of sperm morphological abnormalities and histopathological changes in different body organs. The drug was administrated orally at a dose of81 mg/kg body weight twice daily(Total = 162 mg/kg/day) for various periods of time equivalent to 625 mg/men(twice daily).Results: The results revealed non-significant chromosomal aberrations induced after treatment with amoxicillin/clavulanic acid(AC) in both bone marrow and mouse spermatocytes after 7 and 10 days treatment. On the other hand, statistically significant percentages of sperm morphological abnormalities were recorded. Such percentage reached 8.10 ± 0.55, 9.86 ± 0.63 and 12.12 ± 0.58 at the three time intervals tested(7, 14 and 35 days after the 1 st treatment respectively)(treatment performed for 5 successive days) compared with 2.78 ± 0.48 for the control. The results also revealed histopathological changes in different body organs after AC treatment which increased with the prolongation of the period of therapy. Congestion of central vain, liver hemorrhage and hydropic changes in hepatocytes were noticed in the liver. Degenerative changes were found in kidney glomerulus and tubules while testis showed atrophy of seminiferous tubules, and reduction of spermatogenesis. AC also induced neurotoxicity and altered brain neurotransmitter levels. Hemorrhage in the myocardium, disruption of cardiac muscle fibers and pyknotic nuclei in cardiomyocytes were recorded as side effects of AC in heart tissue.Conclusions: The results concluded that AC treatment induced sperm morphological abnormalities and histopathological changes in different body organs. Clinicians must be aware of such results while describing the drug. 展开更多
关键词 amoxicillin/clavulanic acid GENOTOXICITY Sperm abnormalities Histopathological changes
下载PDF
The Quality and <i>in Vitro</i>Efficacy of Amoxicillin/Clavulanic Acid Formulations in the Central Region of Ghana
8
作者 Henry Nettey Grace Lovia Allotey-Babington +6 位作者 Philip Debrah Ofosua Adi-Dako Manal Shaick Isaac Kintoh Francis Arnansi Makafui Nyagblordzro Marvin Holison 《Pharmacology & Pharmacy》 2014年第1期49-60,共12页
Aim: To assess the quality and in vitro efficacy of five brands of amoxicillin/clavulanic acid tablet, suspension and injectable preparations selected from pharmacies in the Central Region of Ghana. Method: Using a St... Aim: To assess the quality and in vitro efficacy of five brands of amoxicillin/clavulanic acid tablet, suspension and injectable preparations selected from pharmacies in the Central Region of Ghana. Method: Using a Stratified Representation Sampling method, forty preparations (tablets, suspensions and injectable powders) containing amoxicillin and clavulanic acid were sampled from nine different locations within the Central Region of Ghana. To determine drug quality, several procedures, namely, content assay, disintegration and dissolution testing were employed. In vitro drug efficacy was determined by comparing the Minimum Inhibitory Concentrations (MIC’s) obtained with published values. Results: All tablets passed the disintegration test, with disintegration time ranging between six (6) and fifteen (15) minutes. Analyses of all the tablets for drug content showed 100% failure (14 out of 14) for amoxicillin and 14% failure (2 out of 14) for clavulanic acid. Injectable formulations showed similar results. All four (4) samples analyzed for content failed the amoxicillin content assay (0 out of 4) but all passed clavulanic acid assay (4 out of 4). For tablet dissolution tests, there was a 93% (13 out of 14) pass rate for both amoxicillin and clavulanic acid. Content analysis of all suspension formulations involved twenty-two (22) samples from five (5) brands. Only 41% (9 out of 22) passed for both amoxicillin and clavulanic acid. All the other samples failed for either amoxicillin, clavulanic acid or both. Results obtained from drug quality tests were confirmed by in vitro efficacy tests against selected microorganisms. Conclusion: The samples were therefore not of good quality, since content assay is the most crucial test. It is hypothesized that this is due to poor storage conditions, and recommendations, such as air conditioning and more structured procedures along the supply chain, are put forward to counteract this. 展开更多
关键词 amoxicillin clavulanic Acid Minimum INHIBITORY Concentration DISSOLUTION
下载PDF
阿莫西林克拉维酸钾四联疗法对幽门螺杆菌感染患者免疫指标及炎症因子的影响
9
作者 宋丽秀 彭昕 +2 位作者 唐明 向辉 兰姣姣 《医学综述》 CAS 2024年第20期2556-2560,共5页
目的观察阿莫西林克拉维酸钾四联疗法对幽门螺杆菌(Hp)感染患者免疫指标及炎症因子的影响。方法选取2023年1月至2024年1月石河子大学第一附属医院消化科收治的82例Hp感染初诊患者作为研究对象,采用随机数字表法分为对照组和观察组,各41... 目的观察阿莫西林克拉维酸钾四联疗法对幽门螺杆菌(Hp)感染患者免疫指标及炎症因子的影响。方法选取2023年1月至2024年1月石河子大学第一附属医院消化科收治的82例Hp感染初诊患者作为研究对象,采用随机数字表法分为对照组和观察组,各41例。对照组采用阿莫西林胶囊+胶体果胶铋胶囊+克林霉素分散片+艾司奥美拉唑镁肠溶片四联疗法治疗,观察组采用阿莫西林克拉维酸钾片+胶体果胶铋胶囊+克林霉素分散片+艾司奥美拉唑镁肠溶片四联疗法治疗。比较两组患者Hp根除率,治疗前后免疫指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))以及炎症因子[白细胞介素-6(IL-6)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)]水平。结果观察组患者Hp根除率明显高于对照组[95.12%(39/41)比75.61%(31/41)](χ^(2)=6.248,P=0.012)。治疗后,观察组患者CD4^(+)、CD4^(+)/CD8^(+)比值明显高于对照组[(48.3±5.2)%比(42.1±5.5)%、1.76±0.43比1.33±0.53](P<0.01),CD8^(+)明显低于对照组[(22.1±3.2)%比(26.8±3.6)%](P<0.01)。治疗后,观察组患者IL-6、CRP、TNF-α水平均明显低于对照组[(11.4±2.1)mg/L比(15.1±2.8)mg/L、(6.8±1.6)ng/L比(10.4±1.9)ng/L、(16.8±3.2)ng/L比(22.4±3.0)ng/L](P<0.01)。结论针对Hp感染初诊患者,阿莫西林克拉维酸钾四联疗法治疗的Hp根除率明显高于阿莫西林四联疗法,且患者免疫功能改善显著,炎症因子水平控制理想。 展开更多
关键词 幽门螺杆菌感染 阿莫西林 阿莫西林克拉维酸钾 免疫指标 炎症因子
下载PDF
阿莫西林克拉维酸钾联合第三代头孢类抗菌药治疗新生儿肺炎的临床效果及其对肠道菌群的影响
10
作者 蒋伟峰 刘雨露 王战胜 《广州医药》 2024年第2期176-180,共5页
目的分析阿莫西林克拉维酸钾与第三代头孢类抗菌药联合应用于新生儿肺炎患儿的应用效果及其对患儿肠道菌群的影响。方法选择在2021年2月—2022年11月期间于我院新生儿科接受相关治疗的100例新生儿肺炎患儿,依照简单随机化法将患儿分为... 目的分析阿莫西林克拉维酸钾与第三代头孢类抗菌药联合应用于新生儿肺炎患儿的应用效果及其对患儿肠道菌群的影响。方法选择在2021年2月—2022年11月期间于我院新生儿科接受相关治疗的100例新生儿肺炎患儿,依照简单随机化法将患儿分为研究组(n=50)及参照组(n=50)。给予参照组常规新生儿肺炎治疗,在此基础上给予研究组患者阿莫西林克拉维酸钾与第三代头孢类抗菌药的联合治疗。治疗结束后对比两组患儿的血清因子水平、肠道菌落情况、临床疗效以及不良反应发生情况。结果治疗前,两组患儿的血清因子水平、肠道内菌群数量比较差异无统计学意义(P>0.05),治疗后两组患儿的降钙素原(procalcitonin,PCT)、C-反应蛋白(C-reactive protein,CRP)、白细胞计数(white blood cell count,WBC)、肠球菌、肠杆菌、双歧杆菌以及乳酸杆菌水平均有改善(P<0.05),其中研究组的PCT、CRP、WBC、肠球菌、双歧杆菌以及乳酸杆菌数量低于参照组,而研究组的肠杆菌数量高于参照组;同时研究组的临床有效率(94.00%)与参照组的临床有效率(86.00%)比较差异无统计学意义(P>0.05);两组患儿的不良反应发生率比较差异无统计学意义(P>0.05),但其中研究组腹泻的发生率高于参照组(P<0.05)。结论在对新生儿肺炎患儿进行治疗时采取阿莫西林克拉维酸钾单纯治疗与阿莫西林克拉维酸钾+第三代头孢类抗菌药(头孢他啶)的临床疗效相当,联合用药虽能更为显著地减少患儿机体的细菌数量,改善血清因子水平,但更易发生腹泻的并发症,且为了减少耐药性,应适当采用单独用药。 展开更多
关键词 阿莫西林克拉维酸钾 第三代头孢类抗菌药 新生儿肺炎 肠道菌群
下载PDF
高剂量二联疗法与经典四联疗法根除幽门螺杆菌的疗效对比
11
作者 李明贤 朱振浩 《中国现代药物应用》 2024年第11期108-110,共3页
目的探讨比较根除幽门螺杆菌治疗中应用经典四联疗法和高剂量二联疗法的临床效果。方法选取76例幽门螺杆菌检验阳性患者,通过随机数字表法进行分组,即观察组及对照组,均为38例。对照组予以经典四联疗法(阿莫西林+枸橼酸铋钾+艾司奥美拉... 目的探讨比较根除幽门螺杆菌治疗中应用经典四联疗法和高剂量二联疗法的临床效果。方法选取76例幽门螺杆菌检验阳性患者,通过随机数字表法进行分组,即观察组及对照组,均为38例。对照组予以经典四联疗法(阿莫西林+枸橼酸铋钾+艾司奥美拉唑+克拉霉素),观察组予以高剂量二联疗法(阿莫西林+艾司奥美拉唑)。比较两组幽门螺杆菌根除率、不良反应发生率、血清炎症介质[血清肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)和白细胞介素-6(IL-6)]水平。结果对照组幽门螺杆菌根除率为89.47%(34/38),观察组幽门螺杆菌根除率为94.74%(36/38),两组幽门螺杆菌根除率比较不存在显著差异(χ^(2)=0.724,P=0.395>0.05)。与对照组的21.05%比较,观察组不良反应发生率5.26%显著较低,差异显著(P<0.05)。治疗前,两组IL-6、IL-8、TNF-α比较无显著差异(P>0.05);治疗后,两组患者IL-6、IL-8、TNF-α水平均较治疗前降低,且观察组IL-6(3.86±1.03)pg/ml、IL-8(0.06±0.05)pg/L、TNF-α(138.62±26.31)ng/ml均低于对照组的(4.69±1.05)pg/ml、(0.11±0.08)pg/L、(351.62±29.62)ng/ml(P<0.05)。结论根除幽门螺杆菌治疗中应用经典四联疗法和高剂量二联疗法的临床效果相当,但高剂量二联疗法可减少药物不良反应,保障患者健康安全,同时利于改善患者血清炎症因子水平,值得推广应用。 展开更多
关键词 阿莫西林 枸橼酸铋钾 艾司奥美拉唑 克拉霉素 幽门螺杆菌 安全性
下载PDF
克拉霉素致急性短暂性抑郁症不良反应1例分析
12
作者 杨雪婷 何波 +1 位作者 闫鸿丽 李冬梅 《中国药物警戒》 2024年第3期352-354,共3页
目的分析使用克拉霉素致急性短暂性抑郁的不良反应,为临床使用提出预警并及早处置提供参考。方法对1例29岁女性患者应用四联方案(阿莫西林、克拉霉素、泮托拉唑、枸橼酸铋钾)根治幽门螺杆菌感染引起急性短暂性抑郁症进行分析。结果考虑... 目的分析使用克拉霉素致急性短暂性抑郁的不良反应,为临床使用提出预警并及早处置提供参考。方法对1例29岁女性患者应用四联方案(阿莫西林、克拉霉素、泮托拉唑、枸橼酸铋钾)根治幽门螺杆菌感染引起急性短暂性抑郁症进行分析。结果考虑是四联抗幽门螺杆菌感染药物导致的急性短暂性抑郁症,循证学证据表明克拉霉素可能是最易引起急性短暂性抑郁的药物。结论在使用根治幽门螺杆菌感染药物时,医务人员需密切关注患者的情绪变化,若发生急性短暂性抑郁症及时停药,防止患者症状进一步加重。 展开更多
关键词 克拉霉素 阿莫西林 泮托拉唑 枸橼酸铋钾 幽门螺杆菌 抑郁症 药品不良反应
下载PDF
阿莫西林-克拉维酸钾序贯治疗反复下呼吸道感染患儿的疗效 被引量:1
13
作者 章玲玲 闫燕 《西北药学杂志》 CAS 2024年第3期163-167,共5页
目的观察阿莫西林-克拉维酸钾序贯治疗反复下呼吸道感染(recurrent lower respiratory tract infection,RLRTI)患儿的疗效及对潮气肺功能,血清白细胞介素-6(interleukin-6,IL-6)、白细胞介素-8(interleukin-8,IL-8)、白细胞介素-10(inte... 目的观察阿莫西林-克拉维酸钾序贯治疗反复下呼吸道感染(recurrent lower respiratory tract infection,RLRTI)患儿的疗效及对潮气肺功能,血清白细胞介素-6(interleukin-6,IL-6)、白细胞介素-8(interleukin-8,IL-8)、白细胞介素-10(interleukin-10,IL-10)水平的影响。方法纳入近92例RLRTI患儿作为研究对象,用随机数字表法分为观察组和对照组,各46例,应用阿莫西林-克拉维酸钾治疗。对照组静脉滴注7~10 d,观察组序贯治疗(静脉滴注3~5 d,口服混悬剂4~5 d)。比较2组临床疗效、主要症状(发热、咳嗽、喘息和肺啰音)消失时间、白细胞计数(white blood cell count,WBC)恢复时间、住院时间;治疗前后潮气肺功能指标(潮气量、呼吸频率、吸气时间、呼气时间、吸呼比、达峰时间比和达峰容积比)、血清炎症因子(IL-6、IL-8和IL-10)水平,及治疗期间不良反应。结果观察组的治疗总有效率高于对照组(P<0.05);观察组发热、咳嗽、喘息、肺啰音消失时间,WBC恢复时间及住院时间均短于对照组(P<0.05);2组呼吸频率均较治疗前下降(P<0.05),吸气时间、呼气时间、达峰时间比、达峰容积比均较治疗前升高(P<0.05),且观察组达峰时间比、达峰容积比均高于对照组(P<0.05);2组血清IL-6、IL-8水平均较治疗前降低(P<0.05),且观察组低于对照组(P<0.05);IL-10水平均较治疗前升高(P<0.05),且观察组高于对照组(P<0.05);2组治疗期间不良反应发生率比较差异无统计学意义(P>0.05)。结论阿莫西林-克拉维酸钾序贯治疗小儿RLRTI可促进症状恢复,改善潮气肺功能,提高疗效,机制可能与其调节IL-6、IL-8、IL-10等炎症细胞因子的表达水平有关。 展开更多
关键词 阿莫西林-克拉维酸钾 序贯治疗 反复下呼吸道感染 潮气肺功能 炎症因子
下载PDF
钾离子竞争性酸阻滞剂二联疗法根除幽门螺杆菌的改良与探索
14
作者 陈威威 彭若琳 +1 位作者 瞿燚 张振玉 《实用医学杂志》 CAS 北大核心 2024年第19期2806-2812,共7页
幽门螺杆菌感染是萎缩性胃炎、消化性溃疡和胃癌等多种胃肠道疾病的重要致病因素。及时的根除治疗有利于维护患者健康。随着幽门螺杆菌耐药性增加,质子泵抑制剂联合大剂量阿莫西林的二联疗法逐渐得到重视。钾离子竞争性酸阻滞剂是一类... 幽门螺杆菌感染是萎缩性胃炎、消化性溃疡和胃癌等多种胃肠道疾病的重要致病因素。及时的根除治疗有利于维护患者健康。随着幽门螺杆菌耐药性增加,质子泵抑制剂联合大剂量阿莫西林的二联疗法逐渐得到重视。钾离子竞争性酸阻滞剂是一类新型抑酸剂,相比传统的质子泵抑制剂,其起效更快,抑酸作用更持久,更加适用于二联疗法。近年来,学者们对钾离子竞争性酸阻滞剂二联疗法进行了大量探索、改良及验证,现对其研究进展进行综述。 展开更多
关键词 幽门螺杆菌 钾离子竞争性酸阻滞剂 阿莫西林 二联疗法
下载PDF
注射用阿莫西林钠/克拉维酸钾中两组分成盐率的分析
15
作者 王松 于明艳 +2 位作者 赵海云 于升平 陈德俊 《中国抗生素杂志》 CAS CSCD 北大核心 2024年第4期394-398,共5页
目的建立离子色谱法同时测定注射用阿莫西林钠/克拉维酸钾中钠离子与钾离子的含量,通过计算其成盐率,对不同企业样品的成盐工艺进行评价。方法采用IonPacCS12A阳离子交换色谱柱(4mm×250mm)和IonPac CG12A保护柱(4mm×50m m),... 目的建立离子色谱法同时测定注射用阿莫西林钠/克拉维酸钾中钠离子与钾离子的含量,通过计算其成盐率,对不同企业样品的成盐工艺进行评价。方法采用IonPacCS12A阳离子交换色谱柱(4mm×250mm)和IonPac CG12A保护柱(4mm×50m m),检测器为电导检测器,抑制器电流为20mA,以6.7mmol/L甲烷磺酸溶液为淋洗液,流速为1.0 mL/min。结果钠离子浓度在6.01~18.04μg/mL范围内与峰面积呈良好的线性关系(r=0.9999,n=5);平均回收率为100.4%(RSD=0.4%,n=9);钾离子浓度在3.33~9.98μg/mL范围内与峰面积呈良好的线性关系(r=0.9998,n=5);平均回收率为100.2%(RSD=0.5%,n=9)。测定了37批注射用阿莫西林钠/克拉维酸钾中钠和钾的含量,其成盐率分别为1.00~1.13和0.94~1.05。结论本方法可用于注射用阿莫西林钠/克拉维酸钾中钠离子与钾离子的含量测定,各企业样品成盐情况较好,但需关注成盐剂的残留。 展开更多
关键词 注射用阿莫西林钠/克拉维酸钾 成盐率 离子色谱法 钠离子 钾离子
下载PDF
阿莫西林克拉维酸钾及替硝唑综合疗法对胃炎患儿的疗效及对hs-CRP、TNF-α、IL-10水平的影响
16
作者 胡淑娟 《河北医药》 CAS 2024年第1期72-74,79,共4页
目的 研究阿莫西林克拉维酸钾及替硝唑综合疗法对胃炎患儿的疗效及对超敏C-反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白介素-10(IL-10)水平的影响。方法 选择2019年7月至2021年7月收治的84例胃炎患儿,随机双盲对照法将其分为二药联... 目的 研究阿莫西林克拉维酸钾及替硝唑综合疗法对胃炎患儿的疗效及对超敏C-反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白介素-10(IL-10)水平的影响。方法 选择2019年7月至2021年7月收治的84例胃炎患儿,随机双盲对照法将其分为二药联合组及单药治疗组,每组42例。单药治疗组予以阿莫西林克拉维酸钾治疗,二药联合组则于单药治疗组的基础上增用替硝唑治疗。比较2组临床疗效,血清炎症指标及免疫功能指标水平,不良反应发生情况。结果 二药联合组治疗总有效率高于单药治疗组(P<0.05)。治疗前2组hs-CRP、TNF-α以及IL-10水平差异无统计学意义(P>0.05);治疗后,二药联合组血清hs-CRP、TNF-α水平均低于单药治疗组,而血清IL-10水平,高于单药治疗组(P<0.05)。治疗前,2组CD3^(+)、CD4^(+)以及CD8^(+)水平差异无统计学意义(P>0.05);治疗后,二药联合组CD3^(+)、CD4^(+)以及CD8^(+)水平均高于单药治疗组(均P<0.05)。二药联合组不良反应总发生率低于单药治疗组(P<0.05)。结论 阿莫西林克拉维酸钾及替硝唑综合疗法可提高胃炎患儿疗效,尤其是在减轻炎性反应及提高免疫功能方面优势明显,且有效降低不良反应发生风险。 展开更多
关键词 小儿胃炎 阿莫西林克拉维酸钾 替硝唑 炎性反应 免疫功能
下载PDF
头孢呋辛和阿莫西林克拉维酸钾分别联合布地奈德治疗儿童肺炎临床疗效观察
17
作者 毕海霞 沈国民 +1 位作者 周家俊 袁增权 《实用医院临床杂志》 2024年第5期123-126,共4页
目的探讨阿莫西林克拉维酸钾与头孢呋辛分别联合布地奈德治疗儿童肺炎的临床疗效。方法选取2022年1月至2023年4月我院收治的儿童肺炎100例,根据治疗方案不同分为试验组52例(阿莫西林克拉维酸钾联合布地奈德治疗)和对照组48例(头孢呋辛... 目的探讨阿莫西林克拉维酸钾与头孢呋辛分别联合布地奈德治疗儿童肺炎的临床疗效。方法选取2022年1月至2023年4月我院收治的儿童肺炎100例,根据治疗方案不同分为试验组52例(阿莫西林克拉维酸钾联合布地奈德治疗)和对照组48例(头孢呋辛联合布地奈德治疗)。比较两组临床疗效,治疗前后C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)及白介素-6(IL-6)等炎症因子水平;治疗后呼吸道症状及影像学恢复时间;治疗后恶心、食欲不振、皮疹等不良反应发生情况。结果治疗后两组疗效比较,差异无统计学意义(P>0.05);治疗后两组CRP、TNF-α及IL-6水平均改善,且试验组指标低于对照组(P<0.05);试验组呼吸道症状及影像学恢复时间均短于对照组(P<0.05);治疗后两组恶心、食欲不振、皮疹发生情况比较,差异无统计学意义(P>0.05)。结论采用阿莫西林克拉维酸钾与头孢呋辛分别联合布地奈德治疗儿童肺炎,阿莫西林克拉维酸钾疗效可观、安全,更加适用于儿童肺炎患者,可为儿童肺炎的临床治疗提供有效指导。 展开更多
关键词 儿童肺炎 阿莫西林克拉维酸钾 头孢呋辛 布地奈德 临床疗效
下载PDF
阿奇霉素干混悬剂与阿莫西林克拉维酸钾治疗小儿肺炎的临床效果研究
18
作者 郑雪金 汪丹 余奇平 《当代医学》 2024年第16期13-17,共5页
目的探讨应用阿奇霉素干混悬剂与阿莫西林克拉维酸钾治疗小儿肺炎的耐药性。方法选取2020年1月至2022年5月上饶市妇幼保健院收治的106例小儿肺炎患者作为研究对象,采用简单随机化方法分为对照组与观察组,每组53例。对照组采用阿莫西林... 目的探讨应用阿奇霉素干混悬剂与阿莫西林克拉维酸钾治疗小儿肺炎的耐药性。方法选取2020年1月至2022年5月上饶市妇幼保健院收治的106例小儿肺炎患者作为研究对象,采用简单随机化方法分为对照组与观察组,每组53例。对照组采用阿莫西林克拉维酸钾治疗,观察组采用阿奇霉素干混悬剂治疗。比较两组治疗前后免疫功能[IgA、IgM、IgG]、肺功能[第1秒用力呼气容积(forced expiratory volume in the first second,FEV1)、用力肺活量(forced vital capacity,FVC)、最大呼气流速(peak expiratory flow rate,PEF)、用力呼气50%速流(50%maximal expiratory flow,MEF50)]、血清细胞因子[白细胞介素-6(interleukin-6,IL-6)、人干扰素γ(human interferonγ,IFN-γ)、单核细胞趋化蛋白-4(monocyte chemoattractant protein-4,MCP-4)]、临床疗效、不良反应发生情况及症状体征改善时间。结果治疗后,两组血清IgA、IgG、IgM水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗后,两组FEV1、FVC、PEF、MEF50均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清MCP-4、IFN-γ、IL-6水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。观察组咳嗽消失时间、退热时间、肺部啰音消失时间及住院时间均短于对照组,差异有统计学意义(P<0.05)。结论阿奇霉素干混悬剂治疗小儿肺炎疗效显著,可改善患者免疫功能和肺功能,调节细胞因子水平,缩短症状体征改善时间,且安全性较高,值得临床推广应用。 展开更多
关键词 阿奇霉素干混悬剂 阿莫西林克拉维酸钾 小儿肺炎
下载PDF
痰热清注射液联合注射用阿莫西林钠克拉维酸钾治疗小儿支气管肺炎的效果及安全性
19
作者 范宴燕 张倩倩 《临床合理用药杂志》 2024年第15期33-35,39,共4页
目的 观察痰热清注射液联合注射用阿莫西林钠克拉维酸钾治疗小儿支气管肺炎的临床效果及安全性。方法 回顾性选取2020年1月—2022年12月鹰潭市中医院收治的支气管肺炎患儿70例,根据用药方法分为西药组与中药联合组,各35例。西药组患儿... 目的 观察痰热清注射液联合注射用阿莫西林钠克拉维酸钾治疗小儿支气管肺炎的临床效果及安全性。方法 回顾性选取2020年1月—2022年12月鹰潭市中医院收治的支气管肺炎患儿70例,根据用药方法分为西药组与中药联合组,各35例。西药组患儿予注射用阿莫西林钠克拉维酸钾,中药联合组患儿在西药组基础上予痰热清注射液,2组均持续用药1周。比较2组临床疗效,症状及体征消失时间,用药前后肺功能指标、免疫指标、血清炎性因子及不良反应。结果 中药联合组总有效率高于西药组(97.14%vs. 77.14%,χ^(2)=4.590,P=0.032)。中药联合组体温恢复正常时间、呼吸功能改善时间及咳嗽、肺部啰音、肺部病灶消失时间均短于西药组(P<0.05)。用药1周后,2组第1秒用力呼气容积、用力肺活量、呼气流量峰值及免疫球蛋白A、免疫球蛋白G、免疫球蛋白M、血清白介素-2、白介素-10水平高于用药前,血清肿瘤坏死因子-α水平低于用药前,且中药联合组高/低于西药组(P<0.01)。中药联合组与西药组不良反应总发生率比较,差异无统计学意义(5.71%vs. 8.57%,P=1.000)。结论 小儿支气管肺炎采用痰热清注射液联合注射用阿莫西林钠克拉维酸钾治疗的临床效果显著,能够明显改善患儿的肺功能,提高免疫功能,减轻炎性反应,进而促进症状及体征快速消失,且安全性较高。 展开更多
关键词 小儿支气管肺炎 痰热清注射液 注射用阿莫西林钠克拉维酸钾 肺功能 免疫功能 不良反应
下载PDF
牛蒡甘桔汤加减联合阿莫西林克拉维酸钾干混悬剂治疗急性化脓性扁桃体炎患儿的效果
20
作者 谢晓燕 《中国民康医学》 2024年第20期83-85,共3页
目的:观察牛蒡甘桔汤加减联合阿莫西林克拉维酸钾干混悬剂治疗急性化脓性扁桃体炎(AST)患儿的效果。方法:选取2023年6月至2024年5月该院收治的60例AST患儿进行前瞻性研究,按照随机数字表法分为研究组与对照组各30例。对照组采用阿莫西... 目的:观察牛蒡甘桔汤加减联合阿莫西林克拉维酸钾干混悬剂治疗急性化脓性扁桃体炎(AST)患儿的效果。方法:选取2023年6月至2024年5月该院收治的60例AST患儿进行前瞻性研究,按照随机数字表法分为研究组与对照组各30例。对照组采用阿莫西林克拉维酸钾干混悬剂治疗,研究组在对照组基础上联合牛蒡甘桔汤加减治疗,比较两组临床疗效、炎性指标[白细胞计数(WBC)、降钙素原(PCT)、C反应蛋白(CRP)]水平、症状消失时间和住院时间。结果:研究组治疗总有效率为100.00%,明显高于对照组的80.00%,差异有统计学意义(P<0.05);治疗后,两组WBC、PCT、CRP等炎性指标水平低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05);研究组发热、脓性分泌物、咽痛等症状消失时间和住院时间均短于对照组,差异有统计学意义(P<0.05)。结论:牛蒡甘桔汤加减联合阿莫西林克拉维酸钾干混悬剂治疗AST患儿可提高治疗总有效率,缩短症状消失时间和住院时间,降低炎性指标水平,效果优于单纯阿莫西林克拉维酸钾干混悬剂治疗。 展开更多
关键词 牛蒡甘桔汤加减 阿莫西林克拉维酸钾干混悬剂 急性化脓性扁桃体炎 儿童 炎性指标 症状
下载PDF
上一页 1 2 25 下一页 到第
使用帮助 返回顶部